(Q39502910)

12 September 2017

1 reference

title

Overview of clinical experience with ciprofloxacin (English)

1 reference

12 September 2017

A P Ball

1

1 reference

12 September 2017

1 April 1986

1 reference

European journal of clinical microbiology

12 September 2017

1 reference

12 September 2017

5

1 reference

12 September 2017

2

1 reference

12 September 2017

214-219

1 reference

In vitro activity of ciprofloxacin (Bay o 9867)

12 September 2017

1 reference

https://api.crossref.org/works/10.1007%2FBF02013993

In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02013993

Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02013993

Pharmacokinetics of ciprofloxacin after oral and parenteral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02013993

Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02013993

Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02013993

Comparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02013993

Oxolinic Acid in the Treatment of Typhoid Fever Due to Chloramphenicol-Resistant Strains of Salmonella typhi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02013993

Open, prospective study of the clinical efficacy of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02013993

Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02013993

Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients

21 January 2018

1 reference

12 December 2020

The pharmacokinetics of ciprofloxacin in patients with impaired renal function

1 reference

12 December 2020

Quinolones and raised plasma concentrations of theophylline

1 reference

12 December 2020

Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis

1 reference

12 December 2020

In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

1 reference

12 December 2020

Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.

1 reference

12 December 2020

Penetration of ciprofloxacin into bronchial secretions

1 reference

12 December 2020

The activity of ciprofloxacin and other 4-quinolones againstChlamydia trachomatis andMycoplasmas in vitro

1 reference

12 December 2020

Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections

1 reference

12 December 2020

The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents, and factors affecting that activity

1 reference

12 December 2020

Experience with ciprofloxacin in the treatment of various infections caused mainly by Pseudomonas aeruginosa.

1 reference

12 December 2020

Single dose ciprofloxacin for treating gonococcal infections in men.

1 reference

12 December 2020

Experience with ciprofloxacin in vitro and in vivo.

1 reference

12 December 2020

Clinical experience with ciprofloxacin in the USA.

1 reference

12 December 2020

Penetration of ciprofloxacin into gynecological tissues following oral and intravenous administration

1 reference

12 December 2020

Reduced enteral absorption of ciprofloxacin in the presence of antacids

1 reference

12 December 2020

Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria.

1 reference

12 December 2020

Activities of newer quinolones against Legionella group organisms

1 reference

12 December 2020

The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.

1 reference

12 December 2020

Enoxacin raises plasma theophylline concentrations

1 reference

12 December 2020

Ciprofloxacin distribution in prostatic tissue and fluid following oral administration

1 reference

12 December 2020

Treatment of uncomplicated gonococcal urethritis in men with two dosages of ciprofloxacin.

1 reference

12 December 2020

In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.

1 reference

12 December 2020

Oral treatment of Pseudomonas-induced urinary tract infections with ciprofloxacin.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02013993

1 reference

12 September 2017

1 reference

PubMed ID

3013631